TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23354809

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam dosing strategy of 44.44/5.56 mg/kg/dose every 8 or 12 hours
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic models for piperacillin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic models for tazobactam
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic models for piperacillin and tazobactam
Number of subjects: 71
Study: 20872199

Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Flomoxef
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cefmetazole vs Flomoxef
Number of subjects: 91
Study: 18353242

Group type: EXPERIMENTAL
Intervention: HBIG injection every four weeks until labor (experimental group with HBsAg positive)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: HBIG injection every four weeks until labor (experimental group with both HBsAg and HBeAg positive)
Number of subjects: 279

Group type: COMPARATOR
Intervention: No HBIG (control group with HBsAg positive)
Number of subjects: 279

Group type: COMPARATOR
Intervention: No HBIG (control group with both HBsAg and HBeAg positive)
Number of subjects: 279
Study: 16600745

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 73
Study: 12890165

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 120 mg/day for 14 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 240 mg/day for 14 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 480 mg/day for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10976194

Group type: EXPERIMENTAL
Intervention: Lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II)
Number of subjects: 121
Study: 9315415

Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsteroid copper intrauterine device (IUD)
Number of subjects: 0
Study: 8375240

Group type: EXPERIMENTAL
Intervention: imipramine +/‐ mexiletine for deep pain, capsaicin for superficial pain, stretching exercises and metaxalone +/‐ piroxican for muscular pain
Number of subjects: 75

Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 75
Study: 2878490

Group type: EXPERIMENTAL
Intervention: Conventional therapy with two injections a day (CTh)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Insulin pump (CSII)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Multiple injections (MI)
Number of subjects: 39
Study: 30036854

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Injectable disease-modifying therapies (iDMTs)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 141

Group type: COMPARATOR
Intervention: iDMTs
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Fingolimod and iDMTs
Number of subjects: 141
Study: 27456085

Group type: EXPERIMENTAL
Intervention: BADI (Brief Adjustment Disorder Intervention) - internet-based modular program with four modules: Relaxation, Time management, Mindfulness, Strengthening relationships.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group - participants wait one month before gaining access to the BADI intervention.
Number of subjects: 0
Study: 26685634

Group type: EXPERIMENTAL
Intervention: Maxillary vacuum‐formed retainer combined with a mandibular canine‐to‐canine retainer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maxillary vacuum‐formed retainer combined with stripping of the mandibular anterior teeth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prefabricated positioner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer (VFR) combined with a canine‐to‐canine retainer (CTC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three retention methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance levels (excellent or good)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body height, initial crowding, gender
Number of subjects: 0
Study: 22297398

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous zoledronic acid (ZOL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 20350675

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 15

Group type: COMPARATOR
Intervention: Detuned ultrasound
Number of subjects: 15
Study: 18331237

Group type: EXPERIMENTAL
Intervention: Proton MRS (1H MRS) for hepatic fat measurement
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Phosphorus MRS (31P MRS) for ATP measurement
Number of subjects: 244
Study: 15976341

Group type: EXPERIMENTAL
Intervention: Immediate testing for C reactive protein (CRP) and white blood cell count (WBC) before initial consultation (group 1)
Number of subjects: 301

Group type: COMPARATOR
Intervention: No advance testing (group 2)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Immediate testing for CRP and WBC (group 1)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study: 11481623

Group type: EXPERIMENTAL
Intervention: Combination therapy with 6 MU daily of interferon alfa 2b plus 800 mg of ribavirin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monotherapy with 6 MU daily of IFN‐alpha2b
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monotherapy with twice‐daily intravenous administration with 3MU of IFN‐beta
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monotherapy with daily intravenous administration with 6 MU of IFN‐beta
Number of subjects: 44
Study: 9744582

Group type: EXPERIMENTAL
Intervention: Partial flexion true sagittal (FS) MR images
Number of subjects: 23

Group type: COMPARATOR
Intervention: Extension sagittal oblique (ESO) MR images
Number of subjects: 23
Study: 8001404

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with oxygen inhalation
Number of subjects: 34

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 34
Study: 2567873

Group type: EXPERIMENTAL
Intervention: Squatting (Birth Cushion)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Conventional semirecumbent management
Number of subjects: 427
Study: 8132369

Group type: EXPERIMENTAL
Intervention: Daily antibiotic prophylaxis with Phenoxymethylpenicillin (or erythromycin for penicillin-allergic patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 40
Study: 385948

Group type: EXPERIMENTAL
Intervention: LAA alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LAA with BCG-cell wall skeleton as an adjuvant
Number of subjects: 60

Group type: COMPARATOR
Intervention: BCG-cell wall skeleton only
Number of subjects: 60

Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 60
Study: 30503748

Group type: EXPERIMENTAL
Intervention: NTCELL® (intra-striatal delivery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham surgery (control)
Number of subjects: 18
Study: 28329080

Group type: EXPERIMENTAL
Intervention: Patients with GCS<15 (altered mental status)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Patients with GCS=15 (normal mental status)
Number of subjects: 326
Study: 25851632

Group type: EXPERIMENTAL
Intervention: EVE/BEV (everolimus 10 mg/day + bevacizumab 10 mg/kg every 2 weeks)
Number of subjects: 365

Group type: COMPARATOR
Intervention: IFN/BEV (interferon 9 MIU 3 times/week + bevacizumab 10 mg/kg every 2 weeks)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Both EVE/BEV and IFN/BEV
Number of subjects: 365
Study: 23646475

Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XI), intravenously injected with 100 mL QI in 100 mL normal saline, twice daily for seven days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 76
Study: 21494043

Group type: EXPERIMENTAL
Intervention: Real-time group with real-time viewer and polyethylene glycol (500 ml) or metoclopramide (10 mg) if capsule in stomach.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional group without preparation.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Real-time group with real-time viewer.
Number of subjects: 80
Study: 19138700

Group type: EXPERIMENTAL
Intervention: Rod reaction times plotted against the spatial luminance ratio (L(max)/L(min)) between the stimulus and its background.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-cone selective increments and decrements reaction times.
Number of subjects: 0
Study: 17966177

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% foam (n=427)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Vehicle foam (n=420)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Ketoconazole cream (n=210)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Vehicle cream (n=105)
Number of subjects: 1162
Study: 15376308

Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation (LDLT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Deceased donor liver transplantation (DDLT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (LDLT and DDLT)
Number of subjects: 76
Study: 11473852

Group type: COMPARATOR
Intervention: Local anesthesia plus a titrated IV propofol infusion (LA/PI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Minidose lidocaine-fentanyl spinal anesthesia (SAB(MLF))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 9761802

Group type: EXPERIMENTAL
Intervention: Active chiropractic manipulation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Simulated chiropractic manipulation
Number of subjects: 91
Study: 7811016

Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg once daily)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Vancomycin (1 g twice daily)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 635

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 635
Study: 3414546

Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride
Number of subjects: 20
Study: 30269638

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 28523945

Group type: EXPERIMENTAL
Intervention: Menopause-related hormone therapy (MHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25757964

Group type: EXPERIMENTAL
Intervention: Staged PCI for non-infarction related artery (non-IRA) within 7-10 days after AMI (Group A)
Number of subjects: 428
Study: 24311403

Group type: EXPERIMENTAL
Intervention: Enteral nutrition containing omega-3 polyunsaturated fatty acid, antioxidants, and glutamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (fasting)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Corticosteroid administration
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 36
Study: 21205623

Group type: EXPERIMENTAL
Intervention: Cisatracurium 20 µg kg(‐1), followed by four incremental 10 µg kg(‐1) doses, and the remainder of 100 µg kg(‐1)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 2
Study: 18206256

Group type: EXPERIMENTAL
Intervention: Quality assurance process in the ARTSCAN trial
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Quality of treatments
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Database of treatment parameters
Number of subjects: 734
Study: 16861093

Group type: EXPERIMENTAL
Intervention: FEBT 1,080 microg
Number of subjects: 42

Group type: COMPARATOR
Intervention: OTFC 1,600 microg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FEBT 270 to 1,300 microg
Number of subjects: 42
Study: 14631279

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% bupivacaine and 2% lidocaine
Number of subjects: 100
Study: 11513308

Group type: EXPERIMENTAL
Intervention: slow-release caffeine (300 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: melatonin (5 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 9756109

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) monotherapy
Number of subjects: 62
Study: 7734010

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 40 mg/d)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 919
Study: 3180201

Group type: EXPERIMENTAL
Intervention: Flunarizine 20 mg by slow intravenous injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31894015

Group type: EXPERIMENTAL
Intervention: Community Resiliency Model® (CRM) training, a 3-hour session
Number of subjects: 196

Group type: COMPARATOR
Intervention: Nutrition education control group
Number of subjects: 196
Study: 30850112

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing and mupirocin for MRSA carriers
Number of subjects: 339902

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 339902

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing
Number of subjects: 339902

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 339902
Study: 27967328

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PG) dosing algorithm
Number of subjects: 140

Group type: COMPARATOR
Intervention: Previously developed PG algorithm for Greek population
Number of subjects: 140
Study: 25845302

Group type: EXPERIMENTAL
Intervention: Non-absorbable 15 × 10 cm folding slit mesh with absorbable tacks (Group 2)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Partially-absorbable 15 × 10 cm mesh with absorbable tacks (Group 3)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Non-absorbable 15 × 10 cm anatomical mesh fixed with 2 ml fibrin sealant (Group 4)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group: Non-absorbable 15 × 10 cm anatomical mesh fixed with absorbable tacks
Number of subjects: 146
Study: 23978392

Group type: EXPERIMENTAL
Intervention: Dopamine depletion with α‐methylparatyrosine (AMPT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 20977679

Group type: EXPERIMENTAL
Intervention: FTC/TDF (200/300 mg) + BILR 355/r (150/100 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: BILR 355/r (150/100 mg)
Number of subjects: 34
Study: 19875408

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (Ferinject) 200 mg iron i.v. weekly until iron repletion, then monthly until Week 24
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline i.v. (placebo)
Number of subjects: 0
Study: 17122614

Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy (ES) followed by laparoscopic cholecystectomy (LC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Laparoendoscopic rendezvous technique with intraoperative ERCP and ES
Number of subjects: 91
Study: 14756638

Group type: EXPERIMENTAL
Intervention: Combination of excimer laser treatment and topical tacrolimus 0.1% ointment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Aquaphor)
Number of subjects: 8
Study: 11488258

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 9350661

Group type: EXPERIMENTAL
Intervention: Clonidine (150 to 225 micrograms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (0.154 mmol/liter)
Number of subjects: 26
Study: 8404802

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Strength training and flexibility exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 90
Study: 3535811

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg at night
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg at night and Naproxen 500 mg twice daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 62
Study: 28993180

Group type: EXPERIMENTAL
Intervention: Single-tablet regimen of darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg taken once per day for 48 weeks
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Control regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Number of subjects: 1141
Study: 26625418

Group type: EXPERIMENTAL
Intervention: Perturbations delivered along the Antero‐Posterior (AP) direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbations delivered along the Medio‐Lateral (ML) direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-training session aftereffects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbations of different amplitudes
Number of subjects: 0
Study: 25406652

Group type: EXPERIMENTAL
Intervention: CBCT group - mini-implants placed using CBCT data
Number of subjects: 13

Group type: COMPARATOR
Intervention: RVG group - mini-implants placed using two-dimensional digital radiographs and a custom made guide
Number of subjects: 13
Study: 23234029

Group type: EXPERIMENTAL
Intervention: Indirect quantitative cardiotocography (qCTG)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard indirect cardiotocography (CTG)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard indirect cardiotocography (CTG) + fetal blood sampling (FBS)
Number of subjects: 220
Study: 20955872

Group type: EXPERIMENTAL
Intervention: Educational intervention on inhaler use
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine monitoring (Control)
Number of subjects: 94
Study: 18031920

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 15676050

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 microg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 200 microg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 400 microg
Number of subjects: 9
Study: 12593177

Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled long-acting beta 2-mimetics and steroids
Number of subjects: 0
Study: 10511331

Group type: EXPERIMENTAL
Intervention: Severe protein restriction diet (0.30 g/kg/day) supplemented with ketoanalogues (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Moderate protein restriction diet (0.65 g/kg/day) (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison between Group A and Group B
Number of subjects: 50
Study: 7537921

Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (MUFA) for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet rich in polyunsaturated fatty acids (PUFA) for 3 weeks
Number of subjects: 16
Study: 2000757

Group type: EXPERIMENTAL
Intervention: Tc-99m teboroxime imaging
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SPECT imaging with shorter acquisition time and appropriate filtering
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Planar imaging in upright position
Number of subjects: 22
Study: 6240786

Group type: EXPERIMENTAL
Intervention: Thiamphenicol (2.5 g perorally)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Spectinomycin (2.0 g im)
Number of subjects: 152
Study: 30862637

Group type: EXPERIMENTAL
Intervention: Guideline Concordant Care (GCC)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Active Surveillance (AS)
Number of subjects: 1200
Study: 29972310

Group type: EXPERIMENTAL
Intervention: Zofenopril plus amlodipine
Number of subjects: 3488

Group type: COMPARATOR
Intervention: Zofenopril
Number of subjects: 3488
Study: 27382811

Group type: COMPARATOR
Intervention: Normal Saline 0.9% (group I)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (group II)
Number of subjects: 31
Study: 24190844

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Individual adolescent focused therapy (AFT)
Number of subjects: 121
Study: 22832068

Group type: EXPERIMENTAL
Intervention: ERP features
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Frequency power features
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fusion model (combination of ERP and power features)
Number of subjects: 35
Study: 21175514

Group type: EXPERIMENTAL
Intervention: Pediatric emergency physician (EP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Orthopedic resident
Number of subjects: 103
Study: 18684255

Group type: EXPERIMENTAL
Intervention: Ablation for long-lasting persistent AF
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ablation for short-lasting persistent AF
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ablation for paroxysmal AF
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ablation for unsuccessful clinical outcome in long-lasting persistent AF
Number of subjects: 194
Study: 15932557

Group type: EXPERIMENTAL
Intervention: Ligasure haemorrhoidectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional diathermy haemorrhoidectomy
Number of subjects: 30
Study: 14531932

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Passive range of motion (ROM) exercises
Number of subjects: 39
Study: 10320179

Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg in 15 mL of saline (Group Clonidine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline 15 mL (Group Saline)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mL (Group Bupivacaine)
Number of subjects: 45
Study: 8729107

Group type: EXPERIMENTAL
Intervention: 3.2% 18:3n-3
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.4% 18:3n-3
Number of subjects: 27

Group type: COMPARATOR
Intervention: 1.0% 18:3n-3
Number of subjects: 27